Ursofalk 250mg/5ml Suspension
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Ursofalk 250mg/5ml Suspension
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
5ml (= 1 cup) of Ursofalk Suspension contains 250mg of ursodeoxycholic acid (UDCA) as the active ingredient.
The suspension also contains 11.39 mg sodium per 5ml.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oral suspension.
Appearance: white, homogenous oral suspension with small air bubbles and an odour of lemon.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Ursofalk 250mg/5ml Suspension is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder
Paediatric population
Hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years.
4.2 Posology and method of administration
There are no age restrictions on the use of Ursofalk 250mg/5ml suspension in the treatment of PBC and for the dissolution of radiolucent gallstones. The following daily dose is recommended for the various indications:
For the treatment of primary biliary cirrhosis (PBC)
The daily dose depends on body weight, and is approximately 14 ± 2 mg UDCA per kg of body weight.
For the first 3 months of treatment, Ursofalk suspension should be taken divided over the day. When the liver function parameters improve, the daily dose can be administered once a day in the evening.
|
Body weight (kg) |
Daily dose (mg/kg BW) |
Cups* of Ursofalk suspension | |||
|
first 3 months |
subsequently | ||||
|
morning |
midday |
evening |
evening (1 x daily) | ||
|
8 - 11 |
12 - 16 |
- |
% |
% |
/ |
|
12 - 15 |
12 - 16 |
% |
% |
% |
% |
|
16 - 19 |
13 - 16 |
/ |
- |
/ |
1 |
|
20 - 23 |
13 - 15 |
% |
/ |
/ |
1 % |
|
24 - 27 |
13 - 16 |
/ |
/ |
/ |
1 / |
|
28 - 31 |
14 - 16 |
% |
/ |
1 |
1 % |
|
32 - 39 |
12 - 16 |
/ |
/ |
1 |
2 |
|
40 - 47 |
13 - 16 |
/ |
1 |
1 |
2 / |
|
48 - 62 |
12 - 16 |
1 |
1 |
1 |
3 |
|
63 - 80 |
12 - 16 |
1 |
1 |
2 |
4 |
|
81 - 95 |
13 - 16 |
1 |
2 |
2 |
5 |
|
96 - 115 |
13 - 16 |
2 |
2 |
2 |
6 |
|
Over 115 |
2 |
2 |
3 |
7 | |
*One cup (5ml oral suspension) contains 250mg of UDCA.
Ursofalk suspension should be taken in accordance with the dosage regimen given above. The oral suspension must be taken regularly.
The use of Ursofalk suspension in PBC may be continued indefinitely.
For dissolution of cholesterol gallstones:
Approximately 10 mg of UDCA per kg of body weight daily, equivalent to:
|
Body Weight |
Cups* |
Equivalent to ml |
|
51 to 65 kg |
2/ |
12.50 |
|
66 to 80 kg |
3 |
15.00 |
|
81 to 100 kg |
4 |
20.00 |
|
Over 100 kg |
5 |
25.00 |
*One cup (= 5 ml oral suspension) contains 250 mg of ursodeoxycholic acid.
Ursofalk suspension should be taken in the evening at bedtime. The oral suspension must be taken regularly.
The time required for dissolution of gallstones is likely to range from 6 to 24 months depending on stone size and composition.
Follow-up cholecystograms or ultrasound investigation may be useful at 6 month intervals until the gallstones have disappeared.
Treatment should be continued until 2 successive cholecystograms and/or ultrasound investigations 4-12 weeks apart have failed to demonstrate gallstones. This is because these techniques do not permit reliable visualisation of stones less than 2mm in diameter. The likelihood of recurrence of gallstones after dissolution by bile acid treatment has been estimated as up to 50% at 5 years. The efficiency of Ursofalk in treating radio-opaque or partially radio-opaque gallstones has not been tested but these are generally thought to be less soluble than radiolucent stones. Noncholesterol stones account for 10-15% of radiolucent stones and may not be dissolved by bile acids.
Older people : There is no evidence to suggest that any alteration in the adult dose is needed but the relevant precautions should be taken into account.
Paediatric population
Cholesterol rich gallstones and PBC are very rare in children but when they occur, dosage should be related to bodyweight. There are no adequate data on the efficacy and safety in this population.
Hepatobiliary disorders associated with cystic fibrosis
Paediatric population
Children with cystic fibrosis aged 1 month to18 years: 20 mg/kg/day in 2-3 divided doses, with a further increase to 30 mg/kg/day if necessary
Very rarely, children under 10 kg body weight are affected. In this case, a commercially available single-use syringe should be used.
(Please note: a syringe is not provided in the pack)
Up to 10 kg body weight: Dosing 20 mg UDCA/kg/day
Measuring device: single-use 2 ml graduated syringe (not provided)
|
Body weight (kg) |
Ursofalk Suspension (ml) | |
|
Morning |
Evening | |
|
4 |
0.8 |
0.8 |
|
4.5 |
0.9 |
0.9 |
|
5 |
1.0 |
1.0 |
|
5.5 |
1.1 |
1.1 |
|
6 |
1.2 |
1.2 |
|
6.5 |
1.3 |
1.3 |
|
7 |
1.4 |
1.4 |
|
7.5 |
1.5 |
1.5 |
|
8 |
1.6 |
1.6 |
|
8.5 |
1.7 |
1.7 |
|
9 |
1.8 |
1.8 |
|
9.5 |
1.9 |
1.9 |
|
10 |
2.0 |
2.0 |
More than 10 kg body weight (BW): Dosing 20-25 mg UDCA/kg/day
Measuring device: measuring cup
|
Body weight (kg) |
Daily dose UDCA (mg/kg BW) |
*Cups of Ursofalk Suspension | |
|
Morning |
Evening | ||
|
11 - 12 |
21-23 |
/ |
/ |
|
13 - 15 |
21-24 |
/ |
% |
|
16 - 18 |
21-23 |
% |
% |
|
19 - 21 |
21-23 |
% |
1 |
|
22 - 23 |
22-23 |
1 |
1 |
|
24 - 26 |
22-23 |
1 |
1% |
|
27 - 29 |
22-23 |
1% |
1% |
|
30 - 32 |
21-23 |
1% |
1/ |
|
33 - 35 |
21-23 |
1/ |
1/ |
|
36 - 38 |
21-23 |
1/ |
1% |
|
39 - 41 |
21-22 |
1% |
1% |
|
42 - 47 |
20-22 |
1% |
2 |
|
48 - 56 |
20-23 |
2% |
2% |
|
57 - 68 |
20-24 |
2% |
2% |
|
69 - 81 |
20-24 |
3% |
3% |
|
82 - 100 |
20-24 |
4 |
4 |
|
>100 |
4/ |
4/ | |
* Conversion table:
|
Ursofalk suspension |
Ursodeoxycholic acid | |
|
1 cup |
= 5 ml |
= 250 mg |
|
% cup |
= 3.75 ml |
= 187.5 mg |
|
/ cup |
= 2.5 ml |
= 125 mg |
|
% cup |
= 1.25 ml |
= 62.5 mg |
4.3 Contraindications
Ursofalk 250mg/5ml Suspension should not be used in patients with: - acute inflammation of the gall bladder or biliary tract
- occlusion of the biliary tract (occlusion of the common bile duct or cystic duct)
- frequent episodes of biliary colic
- radio-opaque calcified gallstones
- impaired contractility of the gall bladder
- hypersensitivity to bile acids or any excipient of the formulation
When used in hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years:
- unsuccessful portoenterostomy or without recovery of good bile flow in children with biliary atresia.
4.4 Special warnings and precautions for use
Ursofalk 250mg/5ml suspension should be taken under medical supervision.
During the first 3 months of treatment, liver function parameters AST (SGOT), ALT (SGPT) and y-GT should be monitored by the physician every 4 weeks, thereafter every 3 months. Apart from allowing for identification of responders and nonresponders in patients being treated for PBC, this monitoring would also enable early detection of potential hepatic deterioration, particularly in patients with advanced stage PBC.
When used for treatment of advanced stage ofprimary biliary cirrhosis:
In very rare cases decompensation of hepatic cirrhosis has been observed, which partially regressed after the treatment was discontinued.
In patients with PBC, in rare cases the clinical symptoms may worsen at the beginning of treatment, e.g. the itching may increase. In this case the dose should be reduced to 250mg daily and then gradually increased to the recommended dose described in section 4.2.
If diarrhoea occurs, the dose must be reduced and in cases of persistent diarrhoea, the therapy should be discontinued.
When used for dissolution of cholesterol gallstones:
In order to assess therapeutic progress and for timely detection of any calcification of the gallstones, depending on stone size, the gall bladder should be visualised (oral cholecystography) with overview and occlusion views in standing and supine positions (ultrasound control) 6-10 months after the beginning of treatment.
If the gall bladder cannot be visualised on X-ray images, or in cases of calcified gallstones, impaired contractility of the gall bladder or frequent episodes of biliary colic, Ursofalk should not be used.
Female patients taking Ursofalk for dissolution of gallstones should use an effective non-hormonal method of contraception, since hormonal contraceptives may increase biliary lithiasis (see section 4.5. and 4.6.)
One cup (5ml) Ursofalk suspension contains 0.50 mmol (11.39mg) sodium. To be taken into consideration by patients on a controlled sodium diet.
4.5 Interaction with other medicinal products and other forms of interaction
Ursofalk suspension should not be administered concomitantly with colestyramine, colestipol or antacids containing aluminium hydroxide and/or smectite (aluminium oxide), because these preparations bind ursodeoxycholic acid in the intestine and thereby inhibit its absorption and efficacy. Should the use of a preparation containing one of these substances be necessary, it must be taken at least 2 hours before or after Ursofalk suspension.
Ursofalk suspension can affect the absorption of ciclosporin from the intestine. In patients receiving ciclosporin treatment, blood concentrations of this substance should therefore be checked by the physician and the ciclosporin dose adjusted if necessary.
In isolated cases, Ursofalk suspension can reduce the absorption of ciprofloxacin.
In a clinical study in healthy volunteers concomitant use of UDCA (500mg/day) and rosuvastatin (20mg/day) resulted in slightly elevated plasma levels of rosuvastatin. The clinical relevance of this interaction also with regard to other statins is unknown.
UDCA has been shown to reduce the peak plasma concentrations (Cmax) and area under the curve (AUC) of the calcium antagonist nitrendipine in healthy volunteers. Close monitoring of the outcome of concurrent use of nitrendipine and UDCA is recommended. An increase in the dose of nitrendipine may be necessary. An interaction with a reduction of the therapeutic effect of dapsone was also reported. These observations, together with in-vitro findings, could indicate a potential for ursodeoxycholic acid to induce cytochrome P450 3A enzymes. Induction has, however, not been observed in a well-designed interaction study with budesonide, which is a known cytochrome P450 3A substrate.
Oestrogenic hormones and blood cholesterol lowering agents such as clofibrate increase hepatic cholesterol secretion and may therefore encourage biliary lithiasis, which is a counter-effect to ursodeoxycholic acid used for dissolution of gallstones.
4.6 Fertility, pregnancy and lactation
Animal studies did not show an influence of UDCA on fertility (see section 5.3). Human data on fertility effects following treatment with UDCA are not available.
Pregnancy
There are no or limited amounts of data on the use of UDCA in pregnant women. Studies in animals have shown reproductive toxicity during the early phase of gestation (see section 5.3). Ursofalk suspension must not be used during pregnancy unless clearly necessary.
Women of childbearing potential should be treated only if they use reliable contraception: non-hormonal or low-oestrogen oral contraceptive measures are recommended. However, in patients taking Ursofalk for dissolution of gallstones, effective non-hormonal contraception should be used, since hormonal oral contraceptives may increase biliary lithiasis.
The possibility of a pregnancy must be excluded before beginning treatment.
Breastfeeding
According to few documented cases of breastfeeding women milk levels of UDCA are very low and probably no adverse reactions are to be expected in breastfed infants.
4.7 Effects on ability to drive and use machines
UDCA has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable effects
The evaluation of undesirable effects is based on the following frequency data: Very common (> 1/10)
Common (> 1/100 to < 1/10)
Uncommon (> 1/1,000 to < 1/100)
Rare (> 1/10,000 to < 1/1,000)
Very rare/Not known (< 1/10,000/cannot be estimated from available data)
Gastrointestinal disorders:
In clinical trials, reports of pasty stools or diarrhoea during ursodeoxycholic acid therapy were common.
Very rarely, severe right upper abdominal pain has occurred during the treatment of primary biliary cirrhosis.
Hepatobiliary disorders:
During treatment with ursodeoxycholic acid, calcification of gallstones can occur in very rare cases.
During therapy of the advanced stages of primary biliary cirrhosis, in very rare cases decompensation of hepatic cirrhosis has been observed, which partially regressed after the treatment was discontinued.
Skin and subcutaneous disorders: Very rarely, urticaria can occur.
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
United Kingdom
Yellow Card Scheme
Website: www.mhra.gov .uk/yellowcard
4.9 Overdose
Diarrhoea may occur in cases of overdose. In general, other symptoms of overdose are unlikely, because the absorption of UDCA decreases with increasing dose and therefore more is excreted with the faeces.
No specific counter-measures are necessary and the consequences of diarrhoea should be treated symptomatically with restoration of fluid and electrolyte balance.
Additional information on special populations:
Long-term, high-dose UDCA therapy (28-30 mg/kg/day) in patients with primary sclerosing cholangitis (off-label use) was associated with higher rates of serious adverse events.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group/ATC code
Group: Bile Acid Preparation Code: A05AA02 and A05B
UDCA is a bile acid which effects a reduction in cholesterol in biliary fluid primarily by dispersing the cholesterol and forming a liquid-crystal phase. UDCA affects the enterohepatic circulation of bile salts by reducing the ileal reabsorption of endogenous more hydrophobic and potentially toxic salts such as cholic and chenodeoxycholic acids.
In-vitro studies show that UDCA has a direct hepatoprotective effect and reduces the hepatotoxicity of hydrophobic bile salts. Immunological effects have also been demonstrated with a reduction in abnormal expression of HLS Class I antigens on hepatocytes as well as suppression of cytokine and interleukin production.
Cystic fibrosis - Paediatric population
From clinical reports long-term experience up to 10 years and more is available with UDCA treatment in paediatric patients suffering from cystic fibrosis associated hepatobiliary disorders (CFAHD). There is evidence that treatment with UDCA can decrease bile duct proliferation, halt progression of histological damage and even reverse hepatobiliary changes if given at early stage of CFAHD. Treatment with UDCA should be started as soon as the diagnosis of CFAHD is made in order to optimise treatment effectiveness.
5.2 Pharmacokinetic properties
UDCA occurs naturally in the body. When given orally it is rapidly and completely absorbed. It is 96-98% bound to plasma proteins and efficiently extracted by the liver and excreted in the bile as glycine and taurine conjugates. In the intestine some of the conjugates are deconjugated and reabsorbed. The conjugates may also be dehydroxylated to lithocholic acid, part of which is absorbed, sulphated by the liver and excreted via the biliary tract.
5.3 Preclinical safety data
a) Acute toxicity
Acute toxicity studies in animals have not revealed any toxic damage.
b) Chronic toxicity
Subchronic toxicity studies in monkeys showed hepatotoxic effects in the groups given high doses, including functional changes (e.g. liver enzyme changes) and morphological changes such as bile duct proliferation, portal inflammatory foci and hepatocellular necrosis. These toxic effects are most likely attributable to lithocholic acid, a metabolite of ursodeoxycholic acid, which in monkeys - unlike humans - is not detoxified. Clinical experience confirms that the described hepatotoxic effects are of no apparent relevance in humans.
c) Carcinogenic and mutagenic potential
Long-term studies in mice and rats revealed no evidence of UDCA having carcinogenic potential.
In vitro and in vivo genetic toxicology tests with UDCA were negative.
The tests with UDCA revealed no relevant evidence of a mutagenic effect.
d) Toxicity to reproduction
In studies in rats, tail malformations occurred after a dose of 2000mg of UDCA per kg of body weight. In rabbits, no teratogenic effects were found, although there were embryotoxic effects (from a dose of 100 mg per kg of body weight). UDCA had no effect on fertility in rats and did not affect peri-/post-natal development of the offspring.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Benzoic acid (E210)
Citric acid, anhydrous Glycerol
Microcrystalline cellulose Carmellose sodium Sodium chloride
Sodium citrate Sodium cyclamate Propylene glycol Purified water Xylitol
Lemon flavouring 6.2. Incompatibilities
None known other than the interactions identified in Section 4.5.
6.3 Shelf life
Unopened Container: 4 years
After first opening: 4 months
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
250 ml of suspension in an amber glass bottle, closed with a white ribbed child-resistant plastic screw cap (PP/PE). CE marked transparent plastic (PP) cup with 4 embossed graduations: 1.25 ml, 2.5 ml, 3.75 ml and 5 ml.
Pack sizes
Bottles of 250 ml oral suspension.
6.6 Special precautions for disposal
Shake well before use.
Opening the child-resistant closure:
To open the bottle, press down firmly on the cap whilst twisting it to the left.
7. MARKETING AUTHORISATION HOLDER
Dr Falk Pharma UK Ltd Unit K
Bourne End Business Park
Cores End Road
Bourne End
Bucks
SL8 5AS
United Kingdom
8. MARKETING AUTHORISATION NUMBER(S)
PL 10341/0007
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of First Authorisation: 31 December 2004 Date of Last Renewal: 25 February 2010
10
DATE OF REVISION OF THE TEXT
11/11/2014